Adverse Event Management

FDA Approves Eflapegrastim to Decrease Risk of Infection in Patients Receiving Cytotoxic Chemotherapy

September 22, 2022

The FDA has approved eflapegrastim to treat febrile neutropenia. The agent should be administered 24 hours following cytotoxic chemotherapy. It comes with warnings for fatal splenic rupture, acute respiratory distress syndrome, sickle cell crisis, glomerulonephritis, leukocytosis, thrombocytopenia, and myelodysplastic syndrome.

Dose-Optimized Regorafenib Provides Comparable, Safe Option for mCRC

September 15, 2022

Patients with relapsed or refractory metastatic colorectal cancer who received dose-optimized regorafenib achieved superior survival outcomes than those who received best supportive care, fruquintinib, standard-dose regorafenib, and trifluridine/tipiracil.